GPX4 and metabolic dysfunction-associated steatohepatitis: It has been reported that the expression of GPX4 in mouse liver is decreased in the MCD combined with RSL3 mouse model, and treatment with GPX4 activator, iron chelator, or ferroptosis inhibitor can significantly slow the progression of NASH by enhancing GPX4 activity and affecting iron metabolism (Qi et al., 2020).